Glicentin
Also known as: gut glucagon, proglucagon 1-69, enteroglucagon, intestinal glucagon
Endogenous gut peptide hormone; proglucagon-derived peptide; intestinal L-cell secretory product
What it is
Glicentin is a gut hormone made naturally in the intestinal lining, drawing interest among researchers studying digestion, gut repair, and metabolic health. Produced every time you eat, it helps maintain the intestinal mucosa, influences how gut bacteria are managed, and serves as a measurable marker of gut function after bariatric surgery or intestinal disease.
The scientific side
glicentin is a 69-amino acid peptide corresponding to proglucagon residues 1-69, produced in the intestinal L-cells through tissue-specific processing of the proglucagon precursor by prohormone convertase 1/3 (PC1/3). The same precursor in pancreatic alpha-cells is cleaved by prohormone convertase 2 (PC2) to yield glucagon rather than glicentin, illustrating how differential enzymatic processing of a single gene product generates peptides with distinct physiologic roles (PMID 17356847, PMID 15143067). Glicentin contains the full glucagon sequence within its N-terminal extension, and oxyntomodulin (a fragment of glicentin) retains weak glucagon receptor and GLP-1 receptor activity; however, glicentin itself is generally considered biologically inactive or only weakly active at glucagon receptors, serving largely as a circulatory precursor or co-secreted product alongside GLP-1, GLP-2, and oxyntomodulin from L-cells. L-cells are distributed throughout the intestinal epithelium from the small intestine to the rectum, with predominant secretion in the colon, and secrete glicentin postprandially in response to luminal nutrients — particularly dietary fat and oral macronutrient mixtures — with serum levels rising more markedly and persistently after fat intake than after intravenous glucose or lipid infusion. In terms of intestinal trophic function, animal and in vitro studies demonstrate that exogenous glicentin stimulates mucosal cell proliferation in the small intestine. Subcutaneous administration of recombinant rat glicentin at 100 micrograms/kg per day for two weeks increased jejunal wet weight, protein content, DNA content, and alkaline phosphatase activity in rats, with ornithine decarboxylase (ODC) activity also elevated in jejunal mucosa — a marker of proliferative signaling — while the ileum showed less pronounced effects. Separate work in rats with Thiry-Vella fistulas found that glicentin exerts both a systemic trophic effect independent of luminal factors on proximal gut mucosa and an indirect luminal mechanism on distal gut. Following massive small bowel resection in rats, enteroglucagon (measured as predominantly glicentin-sized fragments) rose in parallel with crypt cell production rate, appearing early enough and persisting long enough to mediate intestinal adaptation.
Class: Endogenous gut peptide hormone; proglucagon-derived peptide; intestinal L-cell secretory product
Administration & storage
- Administration
- Subcutaneous injection in rat studies (100 micrograms/kg/day for intestinal mucosal trophic experiments)Intraperitoneal injection in rat studies for acute ODC activity measurementsNo human injection data available; glicentin is not administered to humans in any published clinical protocol
- Storage
- Research-grade recombinant glicentin should be stored at -80°C in single-use aliquots to prevent freeze-thaw degradation. No human pharmaceutical storage guidelines exist. Glicentin is an endogenous peptide and susceptible to proteolytic degradation; plasma samples for glicentin measurement require protease inhibitor cocktails (including DPP-4 inhibitor) added immediately at blood collection and storage at -80°C.
- Cautions
- No human safety data for exogenous glicentin administration are available; no clinical trials have administered glicentin to humans.,Glicentin contains the full glucagon sequence (residues 33-61 of proglucagon); in theory, pharmacologic doses could activate glucagon receptors, causing hyperglycemia, nausea, and vomiting analogous to glucagon administration.,Any off-label or experimental use of synthetic glicentin in humans would constitute an unapproved investigational new drug use under FDA regulations (21 CFR Part 312) and would require an IND.,Peptide contamination and endotoxin levels are critical quality parameters for any research-grade glicentin preparation intended for in vivo use, even in animals.,Consumers purchasing 'glicentin peptide' from research chemical vendors should be aware that no validated human dose, route, or safety profile exists and that the peptide has no established human therapeutic application.
Legal & regulatory status
Glicentin has no FDA-approved therapeutic indication. It is an endogenous peptide produced physiologically by intestinal L-cells from proglucagon processing via prohormone convertase 1/3 (PC1/3). No investigational new…
Glicentin is not listed on the WADA Prohibited List. As an endogenous peptide hormone produced by intestinal L-cells, it is classified in the category of proglucagon-derived peptides. Unlike GLP-1 or growth…
Glicentin is not approved by Health Canada as a drug or biologic product for any therapeutic indication. Its physiologic role as an intestinal hormone derived from the proglucagon gene has been studied in Canadian…
What it's studied for
- Intestinal mucosal trophic support and gut adaptation after small bowel resection Preclinical animal studies (rat) / in vitro cell data
- Intestinal barrier function — inhibition of bacterial translocation In vitro cell study
- Biomarker of glycemic trajectory in prediabetes and diabetes progression Prospective human cohort study
- Postprandial glicentin response as predictor of weight loss success Randomized controlled trial (human, 12-week RCT)
- Glicentin hypersecretion as metabolic mediator after Roux-en-Y gastric bypass surgery Clinical observational / longitudinal cohort
- Postnatal intestinal development and neonatal enteral feeding biomarker Prospective clinical study in neonates
- Potential biomarker for acute intestinal ischemia Prospective single-center clinical study
- Differential postprandial secretion in obesity and in response to dietary macronutrient composition Human interventional physiology studies
Safety signals
- No human exogenous administration safety data — absence of clinical trial evidence
- Potential glucagon receptor activation at supraphysiologic doses — theoretical hyperglycemia risk
- Altered glicentin secretion as indicator of intestinal ischemia or mucosal injury — diagnostic confound
- Elevated glicentin post-bariatric surgery — association with hyperinsulinism and postprandial hypoglycemia risk
- Impaired glicentin secretion associated with deteriorating glucose metabolism in prediabetes
- Potential for assay cross-reactivity leading to measurement errors — glicentin vs. glucagon immunoassay interference
- L-cell tumor (enteroglucagonoma) — glicentin hypersecretion with intestinal dysmotility
All studies (7)
Frequently asked
Does glicentin help heal the gut or repair intestinal lining?
Animal studies suggest glicentin may support intestinal mucosal growth. In rat experiments, injected recombinant glicentin stimulated intestinal cell proliferation and mucosal weight gain, and helped block bacterial entry into intestinal cells in lab dishes. However, no human clinical trials have been conducted with exogenous glicentin, and there are no approved or validated protocols for using it therapeutically in humans for gut repair. Any human use would be off-label, experimental, and without safety or dose data.
Can I buy glicentin as a peptide and inject it to improve my gut health?
Glicentin is not an approved drug, and no validated human dosing protocol exists. Unlike GLP-2 analogues such as teduglutide (which is FDA-approved for short bowel syndrome), glicentin itself has never been tested in human clinical trials. Purchasing and self-injecting research-grade glicentin would mean administering an untested compound at an unknown dose with no human pharmacokinetic or safety data. The risks are unknown, and the potential for glucagon receptor activation (with resultant hyperglycemia) and other off-target effects at pharmacologic doses has not been characterized.
How is glicentin different from GLP-1 or GLP-2?
Glicentin, GLP-1, and GLP-2 all come from the same gene precursor (proglucagon) and are co-secreted by intestinal L-cells after eating. GLP-1 is a potent incretin that stimulates insulin secretion and is the target of semaglutide and other widely used diabetes/obesity drugs. GLP-2 promotes intestinal mucosal growth and is the basis of teduglutide (FDA-approved). Glicentin is the 69-amino acid precursor peptide that contains the glucagon sequence; it is generally considered to have weak receptor activity compared with GLP-1 or GLP-2 and its specific human physiologic role remains under investigation. It can be measured in blood as a marker of L-cell activity and gut health.
Does glicentin go up after gastric bypass surgery?
Yes. Multiple studies show that Roux-en-Y gastric bypass surgery causes a marked and durable elevation of postprandial glicentin levels compared with sleeve gastrectomy or pre-surgery baseline. This elevation persists for at least ten years after surgery and is associated with improved metabolic outcomes. Glicentin and oxyntomodulin are among the most dramatically upregulated proglucagon products after bypass anatomy, likely because nutrients reach the distal small intestine faster, stimulating a larger population of L-cells.
Can glicentin predict diabetes risk?
Research suggests that the trajectory of glicentin levels — how they change over time — may carry prognostic information. Prediabetic individuals who went on to develop type 2 diabetes over one year showed a worsening (lower increase) of postprandial glicentin response compared with those who reverted to normal glucose tolerance. However, a single baseline glicentin measurement in a prediabetic person did not predict future outcomes. Glicentin is being studied as a biomarker of L-cell function and enteroinsular axis health, but it is not yet used clinically for diabetes risk stratification.
Is glicentin the same as enteroglucagon?
Historically yes, with important nuance. 'Enteroglucagon' was the older term for gut glucagon-like immunoreactivity — the material found in intestinal L-cells that cross-reacted with glucagon antibodies. It was later shown to consist primarily of glicentin (proglucagon 1-69) along with its cleavage product oxyntomodulin (proglucagon 33-69). Modern assays distinguish between glicentin and the other proglucagon-derived peptides specifically. The alias 'enteroglucagon' still appears in older literature but is now understood to encompass glicentin as its principal component.